close :

:

Forgotten your password?
 
Drug Information
Side Effects > Arixtra

Arixtra Side Effects

Please note - some side effects for Arixtra may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).


For the consumer

For the professional

Side Effects of Arixtra - for the consumer


Arixtra

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Arixtra:

Bleeding, irritation, rash, or itching at the injection site; chills; constipation; diarrhea; headache; minor bleeding; nausea; sleeplessness; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur when using Arixtra:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black stools; confusion; fever; one-sided weakness; slurred speech; swelling; unusual or severe bleeding or bruising; unusual tiredness or fatigue; vision problems.

Top

For the professional


Arixtra

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying possible adverse events and for approximating rates.

The data described below reflect exposure in 8,877 patients randomized to Arixtra Injection in controlled trials of hip fracture, hip replacement, major knee, or abdominal surgeries, and DVT and PE treatment. Patients received Arixtra primarily in 2 large peri-operative dose-response trials (n = 989), 4 active-controlled peri-operative trials with enoxaparin sodium (n = 3,616), and an extended prophylaxis trial (n = 327), an active-controlled trial with dalteparin sodium (n = 1,425), a dose-response trial in DVT treatment (n = 111), an active-controlled trial with enoxaparin sodium in DVT treatment (n = 1,091), and an active-controlled trial with heparin in PE treatment (n = 1,092).

Hemorrhage

During administration of Arixtra, the most common adverse reactions were bleeding complications.

Hip Fracture, Hip Replacement and Knee Replacement Surgery

The rates of major bleeding events reported during the hip fracture, hip replacement, or knee replacement surgery clinical trials with Arixtra 2.5 mg Injection are provided in Tables 8 and 9 below.

Indications

Peri-Operative Prophylaxis (Day 1 to Day 7 ± 1 post-surgery)

Extended Prophylaxis (Day 8 to Day 28 ± 2 post-surgery)

Fondaparinux Sodium 2.5 mg SC once daily

Enoxaparin Sodium2, 3

Fondaparinux Sodium 2.5 mg SC once daily

Placebo SC once daily

Hip Fracture

18/831 (2.2%)

19/842 (2.3%)

8/327 (2.4 %)4

2/329 (0.6 %)

Hip Replacement

67/2,268 (3.0%)

55/2,597 (2.1%)

Knee Replacement

11/517 (2.1%)5

1/517 (0.2%)

1 Major bleeding was defined as clinically overt bleeding that was (1) fatal, (2) bleeding at critical site (e.g. intracranial, retroperitoneal, intra-ocular, pericardial, spinal, or into adrenal gland), (3) associated with re-operation at operative site, or (4) with a bleeding index (BI) ≥2 calculated as [number of whole blood or packed red blood cell units transfused + [(pre-bleeding)− (post-bleeding)] hemoglobin (g/dL) values].

2 Enoxaparin sodium dosing regimen: 30 mg every 12 hours or 40 mg once daily.

3 Not approved for use in patients undergoing hip fracture surgery .

4 During noncomparative, unblinded, peri-operative prophylaxis, major bleeding was reported in 22/737 (3.0%) patients. Fifteen (15) of these 22 patients continued to receive Arixtra in extended prophylaxis. After randomization, 4/327 (1.2%) patients experienced major bleeding for the first time.

5 p value versus enoxaparin sodium: <0.01, 95% confidence interval: (1.1%, 3.3%) in group receiving Arixtra versus (0.0%, 1.1%) in enoxaparin sodium group.

Table 9. Bleeding Across Randomized, Controlled Hip Fracture, Hip Replacement and Knee Replacement Surgery Studies

Peri-Operative Prophylaxis (Day 1 to Day 7 ± 1 post-surgery)

Extended Prophylaxis (Day 8 to Day 28 ± 2 post-surgery)

Fondaparinux Sodium 2.5 mg SC once daily

Enoxaparin Sodium1, 2

Fondaparinux Sodium 2.5 mg SC once daily

Placebo SC once daily

N = 3,616

N = 3,956

N = 327

N = 329

Major bleeding3

96 (2.7%)

75 (1.9%)

8 (2.4%)4

2 (0.6%)

Fatal bleeding

0 (0.0%)

1 (<0.1%)

0 (0.0%)

0 (0.0%)

Non-fatal bleeding at critical site

0 (0.0%)

1 (<0.1%)

0 (0.0%)

0 (0.0%)

Re-operation due to bleeding

12 (0.3%)

10 (0.3%)

2 (0.6%)

2 (0.6%)

BI ≥25

84 (2.3%)

63 (1.6%)

6 (1.8%)

0 (0.0%)

Minor bleeding6

109 (3.0%)

116 (2.9%)

5 (1.5%)

2 (0.6%)

1 Enoxaparin sodium dosing regimen: 30 mg every 12 hours or 40 mg once daily.

2 Not approved for use in patients undergoing hip fracture surgery.

3 Major bleeding was defined as clinically overt bleeding that was (1) fatal, (2) bleeding at critical site (e.g. intracranial, retroperitoneal, intra-ocular, pericardial, spinal, or into adrenal gland), (3) associated with re-operation at operative site, or (4) with a bleeding index (BI) ≥2.

4 During non-comparative, unblinded, peri-operative prophylaxis, 2 fatal bleeds were reported (one in a 50 kg patient, one in a severe renal failure patient).

5 BI≥2: Overt bleeding associated only with a bleeding index (BI) ≥2 calculated as [number of whole blood or packed red blood cell units transfused + [(pre-bleeding) − (post-bleeding)] hemoglobin (g/dL) values].

6 Minor bleeding was defined as clinically overt bleeding that was not major.

A separate analysis of major bleeding across all randomized, controlled, peri-operative, prophylaxis clinical studies of hip fracture, hip replacement, or knee replacement surgery according to the time of the first injection of Arixtra after surgical closure was performed in patients who received Arixtra only post-operatively. In this analysis, the incidences of major bleeding were as follows: <4 hours was 4.8% (5/104), 4-6 hours was 2.3% (28/1196), 6-8 hours was 1.9% (38/1965). In all studies, the majority (≥75%) of the major bleeding events occurred during the first 4 days after surgery.

Abdominal Surgery

The rates of major bleeding reported during the abdominal surgery clinical trial with Arixtra 2.5 mg are provided in Table 10 below.

Fondaparinux Sodium 2.5 mg SC once daily

Dalteparin Sodium 5,000 IU SC once daily

N = 1,433

N = 1,425

Major bleeding

49 (3.4%)

34 (2.4%)

Fatal bleeding

2 (0.1%)

2 (0.1%)

Non-fatal bleeding at critical site

0 (0.0%)

0 (0.0%)

Other non-fatal major bleeding Surgical site Non-surgical site

38 (2.7%) 9 (0.6%)

26 (1.8%) 6 (0.4%)

Minor bleeding2

31 (2.2%)

23 (1.6%)

1 Major bleeding was defined as bleeding that was (1) fatal, (2) bleeding at the surgical site leading to intervention, (3) non-surgical bleeding at a critical site (e.g. intracranial, retroperitoneal, intra-ocular, pericardial, spinal, or into adrenal gland), or leading to an intervention, and/or with a bleeding index (BI) ≥2. (BI ≥2 calculated as [number of whole blood or packed red blood cell units transfused + [(pre-bleeding) − (post-bleeding)] hemoglobin (g/dL) values].)

2 Minor bleeding was defined as clinically overt bleeding that was not major.

A separate analysis of major bleeding according to the time of the first injection of Arixtra after surgical closure was performed. In this analysis the incidences of major bleeding were as follows: <6 hours was 3.4% (9/263) and 6-8 hours was 2.9% (32/1112).

Treatment of Deep Vein Thrombosis and Pulmonary Embolism:

The rates of bleeding events reported during the DVT and PE clinical trials with the Arixtra injection treatment regimen are provided in Table 11 below.

Fondaparinux Sodium Treatment Regimen

Enoxaparin Sodium 1 mg/kg SC q 12h

Heparin aPTT adjusted IV

N = 2,294

N = 1,101

N = 1,092

Major bleeding2

28 (1.2%)

13 (1.2%)

12 (1.1%)

Fatal bleeding

3 (0.1%)

0 (0.0%)

1 (0.1%)

Non-fatal bleeding at a critical site

3 (0.1%)

0 (0.0%)

2 (0.2%)

Intracranial bleeding

3 (0.1%)

0 (0.0%)

1 (0.1%)

Retro-peritoneal bleeding

0 (0.0%)

0 (0.0%)

1 (0.1%)

Clinically overt bleeding with a 2 g/dL fall in hemoglobin and/or leading to transfusion of PRBC or whole blood ≥2 units

22 (1.0%)

13 (1.2%)

10 (0.9%)

Minor bleeding3

70 (3.1%)

33 (3.0%)

57 (5.2%)

1 Bleeding rates are during the study drug treatment period (approximately 7 days). Patients were also treated with Vitamin K antagonists initiated within 72 hours after the first study drug administration.

2 Major bleeding was defined as clinically overt: - and/or contributing to death − and/or in a critical organ including intracranial, retroperitoneal, intraocular, spinal, pericardial, or adrenal gland − and/or associated with a fall in hemoglobin level ≥2 g/dL − and/or leading to a transfusion≥2 units of packed red blood cells or whole blood.

3 Minor bleeding was defined as clinically overt bleeding that was not major.

Thrombocytopenia

See WARNINGS: Thrombocytopenia.

Local Reactions

Mild local irritation (injection site bleeding, rash, and pruritus) may occur following subcutaneous injection of Arixtra.

Elevations of Serum Aminotransferases

In the peri-operative prophylaxis randomized clinical trials of 7 ± 2 days asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than 3 times the upper limit of normal of the laboratory reference range have been reported in 1.7% and 2.6% of patients, respectively, during treatment with Arixtra 2.5 mg Injection versus 3.2% and 3.9%, of patients, respectively, during treatment with enoxaparin sodium 30 mg every 12 hours or 40 mg once daily enoxaparin sodium. Such elevations are fully reversible and are rarely associated with increases in bilirubin. In the extended prophylaxis clinical trial no significant differences in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels between Arixtra 2.5 mg Injection and placebo treated patients were observed.

In the DVT and PE treatment clinical trials asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than 3 times the upper limit of normal of the laboratory reference range have been reported in 0.7% and 1.3% of patients, respectively, during treatment with the Arixtra injection treatment regimen. In comparison, these increases have been reported in 4.8% and 12.3%, of patients, respectively, in the DVT treatment trial during treatment with enoxaparin sodium 1 mg/kg every 12 hours, and in 2.9% and 8.7%, of patients, respectively, in the PE treatment trial during treatment with aPTT adjusted heparin.

Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease, and pulmonary emboli, elevations that might be caused by drugs like Arixtra should be interpreted with caution.

Other Adverse Events

Other adverse events that occurred during treatment with Arixtra, or enoxaparin sodium in clinical trials with patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery and that occurred at a rate of at least 2% in either treatment group, are provided in Table 12 below. Other adverse events that occurred during treatment with Arixtra or dalteparin sodium in clinical trials with patients undergoing abdominal surgery and that occurred at a rate of at least 2% in either treatment group are provided in Table 13 below. Other adverse events that occurred during treatment with Arixtra, enoxaparin sodium, or heparin in the DVT and PE treatment clinical trials and that occurred at a rate of at least 2% in any treatment group are provided in Table 14 below.

Table 12. Adverse Events Occurring in ≥2% of Patients Treated With Arixtra, Enoxaparin Sodium, or Placebo Regardless of Relationship to Study Drug Across Randomized, Controlled, Hip Fracture Surgery, Hip Replacement Surgery, or Knee Replacement Surgery Studies

Adverse Events

Peri-Operative Prophylaxis (Day 1 to Day 7 ± 1 post-surgery)

Extended Prophylaxis (Day 8 to Day 28 ± 2 post-surgery)

Fondaparinux Sodium 2.5 mg SC once daily

Enoxaparin Sodium1, 2

Fondaparinux Sodium 2.5 mg SC once daily

Placebo SC once daily

N = 3,616

N = 3,956

N = 327

N = 329

Anemia

707 (19.6%)

670 (16.9%)

5 (1.5%)

4 (1.2%)

Fever

491 (13.6%)

610 (15.4%)

1 (0.3%)

4 (1.2%)

Nausea

409 (11.3%)

484 (12.2%)

1 (0.3%)

4 (1.2%)

Edema

313 (8.7%)

348 (8.8%)

3 (0.9%)

2 (0.6%)

Constipation

309 (8.5%)

416 (10.5%)

6 (1.8%)

7 (2.1%)

Rash

273 (7.5%)

329 (8.3%)

2 (0.6%)

4 (1.2%)

Vomiting

212 (5.9%)

236 (6.0%)

2 (0.6%)

4 (1.2%)

Insomnia

179 (5.0%)

214 (5.4%)

3 (0.9%)

1 (0.3%)

Wound drainage increased

161 (4.5%)

184 (4.7%)

2 (0.6%)

0 (0.0%)

Hypokalemia

152 (4.2%)

164 (4.1%)

0 (0.0%)

0 (0.0%)

Urinary tract infection

136 (3.8%)

135 (3.4%)

13 (4.0%)

13 (4.0%)

Dizziness

131 (3.6%)

165 (4.2%)

2 (0.6%)

0 (0.0%)

Purpura

128 (3.5%)

137 (3.5%)

0 (0.0%)

0 (0.0%)

Hypotension

126 (3.5%)

125 (3.2%)

1 (0.3%)

0 (0.0%)

Confusion

113 (3.1%)

132 (3.3%)

4 (1.2%)

1 (0.3%)

Bullous eruption3

112 (3.1%)

102 (2.6%)

0 (0.0%)

1 (0.3%)

Urinary retention

106 (2.9%)

117 (3.0%)

0 (0.0%)

1 (0.3%)

Hematoma

103 (2.8%)

109 (2.8%)

7 (2.1%)

1 (0.3%)

Diarrhea

90 (2.5%)

102 (2.6%)

6 (1.8%)

8 (2.4%)

Dyspepsia

87 (2.4%)

102 (2.6%)

1 (0.3%)

2 (0.6%)

Post-operative hemorrhage

85 (2.4%)

69 (1.7%)

2 (0.6%)

2 (0.6%)

Headache

72 (2.0%)

97 (2.5%)

0 (0.0%)

2 (0.6%)

Pain

62 (1.7%)

101 (2.6%)

0 (0.0%)

0 (0.0%)

Surgical site reaction

29 (0.8%)

41 (1.0%)

5 (1.5%)

8 (2.4%)

1Enoxaparin sodium dosing regimen: 30 mg every 12 hours or 40 mg once daily.

2Not approved for use in patients undergoing hip fracture surgery.

3Localized blister coded as bullous eruption.

Table 13: Adverse Events Occurring in≥ 2% of Patients Treated With Arixtra or Dalteparin Sodium Undergoing Abdominal Surgery Regardless of Relationship to Study Drug

Adverse Events

Fondaparinux Sodium 2.5 mg SC once daily

Dalteparin Sodium 5000 IU SC once daily

N = 1,433

N = 1,425

Post-operative wound infection

70 (4.9%)

69 (4.8%)

Post-operative haemorrhage

61 (4.3%)

42 (2.9%)

Fever

53 (3.7%)

54 (3.8%)

Surgical site reaction

46 (3.2%)

40 (2.8%)

Anaemia

35 (2.4%)

26 (1.8%)

Hypertension

35 (2.4%)

41 (2.9%)

Pneumonia

33 (2.3%)

23 (1.6%)

Vomiting

31 (2.2%)

26 (1.8%)

Table 14. Adverse Events Occurring in≥2% of Patients Treated With Arixtra, Enoxaparin Sodium, or Heparin Regardless of Relationship to Study Drug Across VTE Treatment Studies

Adverse Events

Fondaparinux Sodium

Enoxaparin Sodium

Heparin

N = 2,294

N = 1,101

N = 1,092

Constipation

106 (4.6%)

32 (2.9%)

93 (8.5%)

Headache

104 (4.5%)

37 (3.4%)

65 (6.0%)

Insomnia

86 (3.7%)

19 (1.7%)

75 (6.9%)

Fever

81 (3.5%)

32 (2.9%)

47 (4.3%)

Nausea

76 (3.3%)

29 (2.6%)

53 (4.9%)

Urinary tract infection

53 (2.3%)

20 (1.8%)

24 (2.2%)

Coughing

48 (2.1%)

7 (0.6%)

26 (2.4%)

Diarrhea

43 (1.9%)

22 (2.0%)

27 (2.5%)

Abdominal pain

33 (1.4%)

14 (1.3%)

28 (2.6%)

Chest pain

33 (1.4%)

8 (0.7%)

26 (2.4%)

Leg pain

31 (1.4%)

10 (0.9%)

22 (2.0%)

Back pain

30 (1.3%)

11 (1.0%)

34 (3.1%)

Epistaxis

30 (1.3%)

12 (1.1%)

41 (3.8%)

Prothrombin decreased

30 (1.3%)

3 (0.3%)

34 (3.1%)

Anemia

28 (1.2%)

3 (0.3%)

23 (2.1%)

Vomiting

26 (1.1%)

14 (1.3%)

27 (2.5%)

Hypokalemia

25 (1.1%)

2 (0.2%)

23 (2.1%)

Bruise

24 (1.0%)

24 (2.2%)

14 (1.3%)

Anxiety

18 (0.8%)

8 (0.7%)

22 (2.0%)

Hepatic function abnormal

10 (0.4%)

14 (1.3%)

24 (2.2%)

Hepatic enzymes increased

7 (0.3%)

52 (4.7%)

30 (2.7%)

SGPT increased

7 (0.3%)

47 (4.3%)

8 (0.7%)

SGOT increased

4 (0.2%)

31 (2.8%)

3 (0.3%)

Top

More resources:

Cerner Multum Arixtra injectable

MedFacts Arixtra

Micromedex Arixtra - Includes detailed dosage instructions.

FDA Arixtra

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


Join Drugs.com
Click here to see what benefits you can get by joining our FREE membership programme.
Drugs.com is the most popular, comprehensive, and up-to-date source of drug information online. Providing advice on more than 24,000 prescription drugs and over-the-counter medicines for consumers and professionals .
Advertisement
In The Pipeline